The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis—A Systematic Review and Pooled Analysis
Abstract
Purpose: An often under-recognized late manifestation of prostate adenocarcinoma (PCa) is the development of treatment-related neuroendocrine prostate cancer (NEPC). The aim of this study is to identify the risk factors related to survival after NEPC diagnosis (NEPCS) and time from initial diagnosis of PCa to development of NEPC (TTNEPC). Patients and Methods: A literature search on NEPC was performed using databases such as MEDLINE and EMBASE. Studies were eligible if outcomes data (NEPCS and/or TTNEPC) were reported in patients with a prior history of PCa and histopathologically confirmed NEPC. NEPCS and TTNEPC were evaluated using the Cox regression model with the robust sandwich estimates of the covariance matrix. Results: There were 54 eligible publications, contributing 123 patients. The median TTNEPC was 20 months. In multivariable analyses, the Gleason score was significantly associated with shorter TTNEPC (hazard ratio [HR], 1.66; P = .032). The median NEPCS was 7 months. In multivariable analyses, the number of organs with metastatic disease at NEPC was significantly associated with shorter NEPCS (HR, 3.31; P = .001). Type of treatment after NEPC was significantly associated with longer NEPCS, with HRs of 0.66 (radiotherapy v palliative therapy; P = .034), 0.38 (chemotherapy v palliative therapy; P = .018), and 0.29 (chemoradiotherapy v palliative therapy; P = .012), respectively. Conclusion: Treatment-related NEPC is an often under-recognized late manifestation of PCa with poor prognosis. Our study found that Gleason score was the only independent factor contributing to TTNEPC. Once NEPC is diagnosed, type of treatment and the number of organs with metastatic disease were the most important factors related to survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Beltran, H., Rickman, D. S., Park, K., Chae, S. S., Sboner, A., MacDonald, T. Y., Wang, Y., Sheikh, K. L., Terry, S., Tagawa, S. T., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0130 · Cited by 999
Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
Epstein, J. I., Amin, M. B., Beltran, H., Lotan, T. L., Mosquera, J.-M., Reuter, V. E., Robinson, B. D., Troncoso, P., & Rubin, M. A. (2014) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000208 · Cited by 569
Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975
La Vecchia, C., Bosetti, C., Lucchini, F., Bertuccio, P., Negri, E., Boyle, P., & Levi, F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp530 · Cited by 559
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Aparicio, A. M., Harzstark, A. L., Corn, P. G., Wen, S., Araujo, J. C., Tu, S.-M., Pagliaro, L. C., Kim, J., Millikan, R. E., Ryan, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3791 · Cited by 479
Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980
Bosetti, C., Bertuccio, P., Malvezzi, M., Levi, F., Chatenoud, L., Negri, E., & La Vecchia, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt301 · Cited by 464
Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases
Wang, W., & Epstein, J. I. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318058a96b · Cited by 375
Papandreou, C. N., Daliani, D. D., Thall, P. F., Tu, S.-M., Wang, X., Reyes, A., Troncoso, P., & Logothetis, C. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.065 · Cited by 286
Small cell carcinoma of the prostate
Nadal, R., Schweizer, M., Kryvenko, O. N., Epstein, J. I., & Eisenberger, M. A. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.21 · Cited by 276
Mosquera, J. M., Beltran, H., Park, K., MacDonald, T. Y., Robinson, B. D., Tagawa, S. T., Perner, S., Bismar, T. A., Erbersdobler, A., Dhir, R., et al. (2013) · Neoplasia · doi:10.1593/neo.121550 · Cited by 249
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
Beltran, H., Tagawa, S. T., Park, K., MacDonald, T., Milowsky, M. I., Mosquera, J. M., Rubin, M. A., & Nanus, D. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5166 · Cited by 229
Lapuk, A. V., Wu, C., Wyatt, A. W., McPherson, A., McConeghy, B. J., Brahmbhatt, S., Mo, F., Zoubeidi, A., Anderson, S., Bell, R. H., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4047 · Cited by 196
Evans, A. J., Humphrey, P. A., Belani, J., van der Kwast, T. H., & Srigley, J. R. (2006) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200606000-00003 · Cited by 179
Wright, M. E., Tsai, M.-J., & Aebersold, R. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0031 · Cited by 166
Paraneoplastic cerebellar degeneration
Clouston, P. D., Saper, C. B., Arbizu, T., Johnston, I., Lang, B., Newsom–Davis, J., & Posner, J. B. (1992) · Neurology · doi:10.1212/wnl.42.10.1944 · Cited by 147
Shen, R., Dorai, T., Szaboles, M., Katz, A. E., Olsson, C. A., & Buttyan, R. E. (1997) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(97)00039-2 · Cited by 112
Progression of prostate cancer to neuroendocrine cell tumor
Tanaka, M., Suzuki, Y., Takaoka, K., Suzuki, N., Murakami, S., Matsuzaki, O., & Shimazaki, J. (2001) · International Journal of Urology · doi:10.1046/j.1442-2042.2001.00347.x · Cited by 93
L’épidémiologie des cancers en France en 2010 : comparaison avec les États-Unis
Guérin, S., & Hill, C. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1013 · Cited by 72
Overview of chemotherapy for small cell lung cancer.
Bunn, P. A., & Carney, D. N. (1997) · PubMed · Cited by 63
Miyoshi, Y., Uemura, H., Kitami, K., Satomi, Y., Kubota, Y., & Hosaka, M. (2001) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.00936.x · Cited by 57
McMahon, G. T., Blake, M. A., & Wu, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmcpc0905546 · Cited by 12
Neuroendocrine Prostate Cancer
Beltran, H., Mosquera, J. M., & Rubin, M. A. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_22 · Cited by 6
Cited by
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
The great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Dardenne, E., Beltran, H., Benelli, M., Gayvert, K., Berger, A., Puca, L., Cyrta, J., Sboner, A., Noorzad, Z., MacDonald, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.005 · Cited by 559
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Davies, A. H., Beltran, H., & Zoubeidi, A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.22 · Cited by 431
Patient derived organoids to model rare prostate cancer phenotypes
Puca, L., Bareja, R., Prandi, D., Shaw, R., Benelli, M., Karthaus, W. R., Hess, J., Sigouros, M., Donoghue, A., Kossai, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04495-z · Cited by 361
Metadata
- Authors
- Wang, H. T., Yao, Y. H., Li, B. G., Tang, Y., Chang, J. W., & Zhang, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-10-20
- Volume
- 32
- Issue
- 30
- Pages
- 3383-3390
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2168901797
- Cited by
- 314
- References
- 23
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.